2021
Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119
Emancipator K, Winer E, Lipatov O, Im S, Goncalves A, Muñoz-Couselo E, Lee K, Nowecki Z, Schmid P, Tamura K, Testa L, Witzel I, Ohtani S, Hund S, Kulangara K, Karantza V, Mejia J, Ma J, Jelinic P, Huang L, Cortes J. Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119. Pathology 2021, 53: s47-s48. DOI: 10.1016/j.pathol.2021.06.099.Peer-Reviewed Original Research
2019
Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA. Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. Clinical Cancer Research 2019, 25: 1435-1435. PMID: 30770494, DOI: 10.1158/1078-0432.ccr-18-4266.Peer-Reviewed Original Research
2014
Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009.
Isakoff S, He L, Mayer E, Goss P, Traina T, Carey L, Krag K, Liu M, Rugo H, Stearns V, Come S, Ryan P, Finkelstein D, Hartman A, Garber J, Timms K, Winer E, Ellisen L. Identification of biomarkers to predict response to single-agent platinum chemotherapy in metastatic triple-negative breast cancer (mTNBC): Correlative studies from TBCRC009. Journal Of Clinical Oncology 2014, 32: 1020-1020. DOI: 10.1200/jco.2014.32.15_suppl.1020.Peer-Reviewed Original Research
2011
TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.
Isakoff S, Goss P, Mayer E, Traina T, Carey L, Krag K, Rugo H, Liu M, Stearns V, Come S, Borger D, Quadrino C, Finkelstein D, Garber J, Ryan P, Winer E, Ellisen L. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal Of Clinical Oncology 2011, 29: 1025-1025. DOI: 10.1200/jco.2011.29.15_suppl.1025.Peer-Reviewed Original Research
2009
5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib
Morris P, Chen C, Lin N, Moy B, Come S, Abbruzzi A, Winer E, Norton L, Hudis C, Dang C. 5034 Troponin I and C-reactive protein as biomarkers for changes in left ventricular ejection fraction in patients with early stage breast cancer treated with dose-dense doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel with trastuzumab and lapatinib. European Journal Of Cancer Supplements 2009, 7: 271. DOI: 10.1016/s1359-6349(09)70926-7.Peer-Reviewed Original Research